US 12,365,724 B2
Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
Einar M. Sigurdsson, Scarsdale, NY (US)
Assigned to NEW YORK UNIVERSITY, New York, NY (US)
Appl. No. 17/312,854
Filed by NEW YORK UNIVERSITY, New York, NY (US)
PCT Filed Dec. 10, 2019, PCT No. PCT/US2019/065461
§ 371(c)(1), (2) Date Jun. 10, 2021,
PCT Pub. No. WO2020/123492, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/777,511, filed on Dec. 10, 2018.
Prior Publication US 2022/0041697 A1, Feb. 10, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01)] 18 Claims
 
1. An antibody-based molecule that binds to an epitope of Tau, the epitope present in the Tau sequence of TDHGAEIVYK{P}SPVVSGDT{P}SPRHL (SEQ ID NO:1), wherein the antibody-based molecule comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain, the VH domain comprising a heavy chain complementarity-determining region 1 (H-CDR1) comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain complementarity-determining region 2 (H-CDR2) comprising the amino acid sequence of SEQ ID NO: 3, and a heavy chain complementarity-determining region 3 (H-CDR3) comprising the amino acid sequence of SEQ ID NO: 4, and the VL domain comprising a light chain complementarity-determining region 1 (L-CDR1) comprising the amino acid sequence of SEQ ID NO: 5, a light chain complementarity-determining region 2 (L-CDR2) comprising the amino acid sequence of SEQ ID NO: 6, and a light chain complementarity-determining region 3 (L-CDR3) comprising the amino acid sequence of SEQ ID NO: 7.